Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, or adalimumab in patients with active psoriatic arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs: OPAL Broaden, a randomized, placebo-controlled, phase 3 trial

被引：0

作者：

Mease, Philip ^{[1
,2
]}

Hall, Stephen ^{[3
,4
]}

FitzGerald, Oliver ^{[5
,6
]}

van der Heijde, Desiree ^{[7
]}

Merola, Joseph ^{[8
]}

Avila-Zapata, Francisco ^{[9
]}

Graham, Daniela ^{[10
]}

Wang, Cunshan ^{[10
]}

Kanik, Keith ^{[10
]}

机构：

[1] Swedish Med Ctr, Englewood, CO 80110 USA

[2] Univ Washington, Seattle, WA 98195 USA

[3] Cabrini Hlth, Malvern, Vic, Australia

[4] Monash Univ, Clayton, Vic, Australia

[5] St Vincents Univ Hosp, Dublin, Ireland

[6] Univ Coll, Conway Inst, Dublin, Ireland

[7] Leiden Univ, Med Ctr, Leiden, Netherlands

[8] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA

[9] Ctr Multidisciplinario Desarrollo Especializado I, Merida, Mexico

[10] Pfizer Inc, New York, NY USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2017年 / 76卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

4726

引用

页码：AB114 / AB114

页数：1

共 50 条

[1] EFFICACY AND SAFETY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, OR ADALIMUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CSDMARDS): A RANDOMISED, PLACEBO-CONTROLLED, PHASE 3 TRIAL
Mease, P. J.
Hall, S.
FitzGerald, O.
van der Heijde, D.
Merola, J. F.
Avila-Zapata, F.
Cieslak, D.
Graham, D.
Wang, C.
Menon, S.
Hendrikx, T.
Kanik, K. S.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 141 - 142
[2] Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, or Adalimumab in Patients with Active Psoriatic Arthritis and an Inadequate Response to Conventional Synthetic Dmards: A Randomized, Placebo-Controlled, Phase 3 Trial
Mease, Philip J.
Hall, Stephen
FitzGerald, Oliver
van der Heijde, Desiree
Merola, Joseph F.
Avila-Zapata, Francisco
Cieslak, Dorata
Graham, Daniela
Wang, Cunshan
Menon, Sujatha
Hendrikx, Thijs
Kanik, Keith
[J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
[3] Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden - a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
Strand, Vibeke
de Vlam, Kurt
Covarrubias-Cobos, Jose A.
Mease, Philip J.
Gladman, Dafna D.
Graham, Daniela
Wang, Cunshan
Cappelleri, Joseph C.
Hendrikx, Thijs
Hsu, Ming-Ann
[J]. RMD OPEN, 2019, 5 (01):
[4] Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors: OPAL Beyond, a Randomized, Double Blind, Placebo-Controlled, Phase 3 Trial
Gladman, Dafna D.
Rigby, William
Azevedo, Valderilio F.
Behrens, Frank
Blanco, Ricardo
Kaszuba, Andrzej
Kudlacz, Elizabeth
Wang, Cunshan
Menon, Sujatha
Hendrikx, Thijs
Kanik, Keith S.
[J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
[5] Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumor necrosis factor inhibitors: OPAL Beyond, a randomized, double blind, placebo-controlled, phase 3 trial
Gladman, Dafna
Rigby, William
Azevedo, Valderilio
Behrens, Frank
Blanco, Ricardo
Kaszuba, Andrzej
Wang, Cunshan
Menon, Sujatha
Hendrikx, Thijs
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB114 - AB114
[6] Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs
Charles-Schoeman, Christina
Burmester, Gerd
Nash, Peter
Zerbini, Cristiano A. F.
Soma, Koshika
Kwok, Kenneth
Hendrikx, Thijs
Bananis, Eustratios
Fleischmann, Roy
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (07) : 1293 - 1301
[7] EFFICACY AND SAFETY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: OPAL BEYOND, A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL
Gladman, D. D.
Rigby, W. F. C.
Azevedo, V. F.
Behrens, F.
Blanco, R.
Kaszuba, A.
Kudlacz, E.
Wang, C.
Menon, S.
Hendrikx, T.
Kanik, K. S.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 135 - 136
[8] A randomized, double-blind, active-and placebo-controlled phase 3 study of efficacy and safety of ixekizumab, adalimumab, and placebo therapy in patients naive to biologic disease-modifying antirheumatic drugs with active psoriatic arthritis
Mease, P. J.
van der Heijde, D.
Ritchlin, C. T.
Cuchacovich, R. S.
Shuler, C. L.
Lin, C.
Vangerow, H.
Samanta, S.
Lee, C. H.
Gladman, D. D.
[J]. EXPERIMENTAL DERMATOLOGY, 2017, 26 (03) : E30 - E30
[9] Filgotinib, an Oral, Selective Janus Kinase 1 Inhibitor, Is Effective in Psoriatic Arthritis Patients with an Inadequate Response to Conventional Disease-Modifying Anti-Rheumatic Drugs: Results from a Randomized, Placebo-Controlled, Phase 2 Study
Mease, Philip J.
Gladman, Dafna D.
van den Bosch, Filip
Rychlewska-Hanczewska, Anna
Dudek, Anna
Tasset, Chantal
Meuleners, Luc
Harrison, Pille
Besuyen, Robin
Kunders, Rebecca
Mozaffarian, Neelufar
Coates, Laura C.
Helliwell, Philip
[J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
[10] Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials
Song, Gwan Gyu
Bae, Sang-Cheol
Lee, Young Ho
[J]. KOREAN JOURNAL OF INTERNAL MEDICINE, 2014, 29 (05): : 656 - 663

← 1 2 3 4 5 →